Elkan Gamzu

Dr. Gamzu has worked in the biopharmaceutical industry since 1971, in discovery with Hoffmann La Roche, in clinical management and drug development with Warner-Lambert, where as VP, Drug Development had responsibility for the development of Cognex, the first drug approved for Alzheimer’s, and Neurontin. Dr. Gamzu served as CEO of Cambridge Neuroscience and as Interim VP of Development Project Leadership for Millennium Pharmaceuticals. He is a co-founder of BioPharmAnalysis, LLC, a company offering due diligence services and currently serves as Principal of enERGetics, LLC, a biopharmaceutical consulting company. Dr. Gamzu currently serves the boards of directors of Pharmos Corp. (NASDAQ: PARS) and Neurotech S.A.